CorMedix Inc. (NYSEAMERICAN:CRMD) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,715,967 shares, an increase of 28.2% from the October 13th total of 2,118,383 shares. Approximately 4.9% of the shares of the company are short sold. Based on an average daily trading volume, of 944,548 shares, the days-to-cover ratio is currently 2.9 days.
CorMedix (NYSEAMERICAN:CRMD) opened at $0.50 on Friday. CorMedix has a 52-week low of $0.32 and a 52-week high of $2.48.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of CorMedix from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Monday, August 14th. HC Wainwright set a $4.00 price target on shares of CorMedix and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Rodman & Renshaw lowered their price target on shares of CorMedix from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 10th.
TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/18/cormedix-inc-crmd-sees-significant-increase-in-short-interest.html.
CorMedix Company Profile
CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
What are top analysts saying about CorMedix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CorMedix Inc. and related companies.